It was shown to inhibit tumor growth in several in vitro and in vivo cancer models, independent of p53 and retinoic acid receptor signaling pathways [23] in ovarian carcinoma; adult T-cell leukemia/lymphoma; rhabdomyosarcoma; and breast, CRC, and prostate cancer [8,11,12,24,25,26]. The gene discussed is TP53; the disease is prostate cancer.